Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer

Sharifi, Roohollah; Lee, M; Clayton, Michael; Lamb, Damon G.; Siami, Paul; Strub, Marion; Albert, D.J.; Sarosdy, Michael F.

doi:10.1097/00001813-199104000-00005

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, instillation of 10 mg of mitoxantrone resulted in a recurrence rate of 33.92% and the administration of 20 mg resulted in 31.48% recurrence rate, while instillation of 100 MU of IFN·-2b resulted in 28.3% recurrence rate. The recurrence rate for the dose of 10 mg of mitoxantrone is comparable with the 36.3% recorded by Sharifi et al [13] and the 37% reported by Yaman et al [14], while for the dose of 20 mg of mitoxantrone it is comparable with the 35.5% recorded by Namasivayam et al [15]. The recurrence rate for the dose of 100 MU of IFN·-2b is comparable with the 33.3% reported by Da Silva et al [12], while the observed difference can be attributed to the longer follow-up (33.3 months) of the latter study.…”

Section: Discussionsupporting

confidence: 86%

“…Stewart et al [16] noted that nearly 75% of the instilled mitoxantrone was recovered in urine after treatment, implying that the remainder of the drug was absorbed. It has been documented that the side effects of mitoxantrone are in proportion with the dose, the bladder retention time, and the dosage intervals [13,15,16,19]. On the contrary, it has been documented that IFN·-2b toxicity is minor, regardless of the instilled dose [11,12].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Intravesical Mitoxantrone versus Recombinant Interferon-α after Transurethral Resection of Superficial Bladder Cancer: A Randomized Prospective Study

et al. 2004

View full text Add to dashboard Cite

Objective: To determine the efficacy and safety of two different doses of intravesical mitoxantrone and of recombinant interferon-α (IFNα-2b), instilled after transurethral resection (TUR) of superficial transitional cell carcinoma (TCC) of the bladder. Material and Methods: 208 patients (mean age 62.05 years) with primary or recurrent superficial (TaG1, T1G1, T1G2) bladder cancer were randomly allocated into four groups, after TUR of all visible tumors. Group A (45 patients) received no further therapy; group B (56 patients) received 10 mg of mitoxantrone (6 weekly and 20 fortnightly instillations), group C (54 patients) 20 mg of mitoxantrone (3 fortnightly and 10 monthly instillations) and group D (53 patients) received 100 MU of IFNα-2b (8 weekly, 8 fortnightly and 6 monthly instillations). Results: During the follow-up (mean 21.09 months), 29 (64.44%) patients in group A had recurrence, compared with 19 (33.92%) in group B, 17 (31.48%) in group C and 15 (28.3%) patients in group D (p < 0.005). Furthermore, the differences in simple recurrence rates were statistically more significant (p < 0.05), when group A was compared with the three other groups in the terms of T1G2, recurrent and multiple neoplasms. Twenty-nine patients (10, 7, 8, and 4 in groups A–D) experienced tumor progression, and the differences between the four groups were not statistically significant (p > 0.05). The mean recurrence time was 9.03 months in group A, 13.74 in group B, 14.24 in group C and 17.4 months in group D (p < 0.001), and the recurrence rate per 100 patient-months was 4.39, 1.57, 1.48 and 1.06, respectively (p < 0.05). Toxicity (grade 1–3) was recorded in 23.21% in group B, in 31.48% in group C and in 9.43% in group D (p < 0.01). Conclusion: The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects. In comparison with mitoxantrone, the adjuvant intravesical immunotherapy with 100 MU of IFNα-2b showed a better combination of efficacy and safety.

show abstract